Emerging RNA RealSeq is building a liquid biopsy platform centered on cf-RNA fragmentomics and RNA fragment analysis, presenting an opportunity to upsell to labs and pharma partners seeking advanced non-invasive diagnostics in oncology, infectious disease, and fungal pathogens.

Niche Focus Targets scarce, high-need diseases such as Valley Fever and other fungal pathogens with rising prevalence due to climate factors, offering a potential entry point for collaborations, grants-driven pilots, and joint development opportunities.

Funding Validation Recent NHGRI grant funding demonstrates external validation and early-stage investor/grant interest, which can be leveraged to attract co-development deals, sponsored research, or milestone-driven collaborations with larger biotech players.

Technical Differentiation Proprietary bias-free small RNA/miRNA library construction and targeted NGS tools position RealSeq to offer complementary workflows to existing sequencing platforms, suggesting partnerships with sequencing providers and CROs seeking assay diversification.

Growth Readiness Small company with lean team and global potential; relationships with larger peers and scalable solutions can be accelerated through channel partnerships, OEM licensing, and early access programs for academia and biotech customers seeking rapid deployment of liquid biopsy capabilities.